StreetInsider.com News Articles

Form 20-F BetterLife Pharma Inc. For: Jan 31

Mon, 01 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260601/26584076.html

Form 20-F BetterLife Pharma Inc. For: Jan 31

Mon, 01 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260601/26584076.html

Form 20-F BetterLife Pharma Inc. For: Jan 31

Mon, 01 Jun 2026 16:25:00 -0400

si-local-file:///var/storage/secattach/20260601/26584076.html

BetterLife Pharma names Doug Drysdale as Executive Chairman

Wed, 13 May 2026 08:05:45 -0400

BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) announced the appointment of Doug Drysdale as Executive Chairman and Director. Drysdale previously served as CEO of Cybin Inc. (NYSE: CYBN) and has been working as a corporate advisor for BetterLife.

During his tenure at Cybin, Drysdale led the company from molecule inception to Phase 3 trials over three years. The company granted Drysdale stock options to purchase 3,500,000 common shares at an exercise price of $0.065, with monthly vesting over 24 months and a 10-year term.

"We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored

BetterLife Pharma names Doug Drysdale as Executive Chairman

Wed, 13 May 2026 08:05:45 -0400

"We are delighted to welcome Doug to our Board of Directors. His proven global leadership, underscored

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - May 13, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company, is pleased to announce it has appointed Doug Drysdale, currently BetterLife's corporate advisor and formerly CEO of Cybin Inc. ("Cybin") (NYSE: CYBN), as Executive Chairman and Director.

At Cybin, Mr. Drysdale led the company's strategy and team build-out, taking it from molecule inception to Phase 3 trials in just three years. Mr. Drysdale is known as a vocal advocate for revolutionizing mental healthcare through numerous speaking engagements, panel participations, and media interviews.

"We are delighted

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

"We are delighted

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

"We are delighted

BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director

Wed, 13 May 2026 08:00:00 -0400

"We are delighted

Form 6-K BetterLife Pharma Inc. For: Apr 13

Mon, 13 Apr 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260413/26305082.html

Form 6-K BetterLife Pharma Inc. For: Apr 13

Mon, 13 Apr 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260413/26305082.html

Form 6-K BetterLife Pharma Inc. For: Apr 13

Mon, 13 Apr 2026 14:00:00 -0400

si-local-file:///var/storage/secattach/20260413/26305082.html

BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco

Tue, 06 Jan 2026 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Francisco, California, during JPM Week.

The YAFO Capital Access Asia Partnering Forum brings together innovative life science companies and leading investors, pharmaceutical partners, and strategic advisors, with a particular focus on fostering collaboration between North American and Asian capital

BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco

Tue, 06 Jan 2026 08:00:00 -0400

BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital

Thu, 11 Dec 2025 08:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotech company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD"), is pleased to announce it has signed an engagement agreement with Shanghai-based YAFO Capital ("YAFO"), as its exclusive advisor to seek strategic partnerships for development of BETR-001 in the Greater China regions, including mainland China, Hong Kong, Taiwan and Macau. Pursuant to the agreement, BetterLife intends to retain YAFO on a non-exclusive basis for territories outside of Greater China.

Dr. Ahmad Doroudian, CEO

BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital

Thu, 11 Dec 2025 08:00:00 -0400

Dr. Ahmad Doroudian, CEO

BetterLife Announces Debt Settlements